NICE Gives Green Light to Multiple Sclerosis Drug

Pavankumar Kamat

February 21, 2020

The National Institute for Health and Care Excellence (NICE) has recommended peginterferon beta-1a (Plegridy, Biogen Idec) as a treatment option for relapsing-remitting multiple sclerosis (MS) for routine use within NHS England.

Peginterferon beta-1a is recommended for the treatment of adults with relapsing-remitting MS, within its marketing authorisation. The drug has been licensed for the same since 2014.

The recommended dose for peginterferon beta-1a is 125 µg administered subcutaneously every two weeks. Clinical trial evidence has shown peginterferon beta-1a to slow disease progression and decrease the frequency of relapses compared with placebo. Indirect comparison of peginterferon beta-1a with other beta interferons and glatiramer acetate has shown comparable effectiveness; however, peginterferon beta-1a needs to be injected less frequently than other beta interferons.

NICE has determined the cost-effectiveness estimates for peginterferon beta-1a to be favourable for use within the NHS.

In May 2018, NICE had conducted a review of several MS drugs and was unable to make a recommendation on peginterferon beta-1a at that time. However, NICE has reversed its earlier decision after a separate appraisal.

Commenting on the decision in a news release, David Martin, chief executive officer of the Multiple Sclerosis Trust, said: "We are pleased that NICE has approved Plegridy for people with relapsing-remitting MS."

Adapted from Univadis from Medscape.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: